292 related articles for article (PubMed ID: 23940218)
41. Progress in the diagnosis and treatment of rhabdomyosarcoma and related soft tissue sarcomas.
Ruymann FB; Grovas AC
Cancer Invest; 2000; 18(3):223-41. PubMed ID: 10754991
[TBL] [Abstract][Full Text] [Related]
42. Cytodifferentiation and clinical outcome after chemotherapy and radiation therapy for rhabdomyosarcoma (RMS).
Smith LM; Anderson JR; Coffin CM
Med Pediatr Oncol; 2002 Jun; 38(6):398-404. PubMed ID: 11984800
[TBL] [Abstract][Full Text] [Related]
43. Sclerosing rhabdomyosarcomas in children and adolescents: a clinicopathologic review of 13 cases from the Intergroup Rhabdomyosarcoma Study Group and Children's Oncology Group.
Chiles MC; Parham DM; Qualman SJ; Teot LA; Bridge JA; Ullrich F; Barr FG; Meyer WH;
Pediatr Dev Pathol; 2004; 7(6):583-94. PubMed ID: 15630526
[TBL] [Abstract][Full Text] [Related]
44. Genomic gains and losses are similar in genetic and histologic subsets of rhabdomyosarcoma, whereas amplification predominates in embryonal with anaplasia and alveolar subtypes.
Bridge JA; Liu J; Qualman SJ; Suijkerbuijk R; Wenger G; Zhang J; Wan X; Baker KS; Sorensen P; Barr FG
Genes Chromosomes Cancer; 2002 Mar; 33(3):310-21. PubMed ID: 11807989
[TBL] [Abstract][Full Text] [Related]
45. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Raney RB; Walterhouse DO; Meza JL; Andrassy RJ; Breneman JC; Crist WM; Maurer HM; Meyer WH; Parham DM; Anderson JR
J Clin Oncol; 2011 Apr; 29(10):1312-8. PubMed ID: 21357783
[TBL] [Abstract][Full Text] [Related]
46. Fusion transcripts as liquid biopsy markers in alveolar rhabdomyosarcoma and synovial sarcoma: A report of the Cooperative Weichteilsarkom Studiengruppe (CWS).
Stegmaier S; Sparber-Sauer M; Aakcha-Rudel E; Münch P; Reeh T; Feuchtgruber S; Hallmen E; Blattmann C; Bielack S; Klingebiel T; Koscielniak E
Pediatr Blood Cancer; 2022 Sep; 69(9):e29652. PubMed ID: 35338758
[TBL] [Abstract][Full Text] [Related]
47. Adolescents and young adults with rhabdomyosarcoma: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Harrison DJ; Qumseya A; Xue W; Arnold M; Lautz TB; Hiniker SM; Thomas SM; Venkatramani R; Weiss AR; Mascarenhas L
Pediatr Blood Cancer; 2024 Apr; 71(4):e30847. PubMed ID: 38282125
[TBL] [Abstract][Full Text] [Related]
48. Different expression profiles of Y-box-binding protein-1 and multidrug resistance-associated proteins between alveolar and embryonal rhabdomyosarcoma.
Oda Y; Kohashi K; Yamamoto H; Tamiya S; Kohno K; Kuwano M; Iwamoto Y; Tajiri T; Taguchi T; Tsuneyoshi M
Cancer Sci; 2008 Apr; 99(4):726-32. PubMed ID: 18377424
[TBL] [Abstract][Full Text] [Related]
49. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.
Raney RB; Anderson JR; Barr FG; Donaldson SS; Pappo AS; Qualman SJ; Wiener ES; Maurer HM; Crist WM
J Pediatr Hematol Oncol; 2001 May; 23(4):215-20. PubMed ID: 11846299
[TBL] [Abstract][Full Text] [Related]
50. The effect of radiation timing on patients with high-risk features of parameningeal rhabdomyosarcoma: an analysis of IRS-IV and D9803.
Spalding AC; Hawkins DS; Donaldson SS; Anderson JR; Lyden E; Laurie F; Wolden SL; Arndt CA; Michalski JM
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):512-6. PubMed ID: 24074925
[TBL] [Abstract][Full Text] [Related]
51. Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma.
Zibat A; Missiaglia E; Rosenberger A; Pritchard-Jones K; Shipley J; Hahn H; Fulda S
Oncogene; 2010 Dec; 29(48):6323-30. PubMed ID: 20818440
[TBL] [Abstract][Full Text] [Related]
52. Alveolar rhabdomyosarcoma with regional nodal involvement: Results of a combined analysis from two cooperative groups.
Gallego S; Chi YY; De Salvo GL; Li M; Merks JHM; Rodeberg DA; van Scheltinga ST; Mascarenhas L; Orbach D; Jenney M; Million L; Minard-Colin V; Wolden S; Zanetti I; Parham DM; Mandeville H; Venkatramani R; Bisogno G; Hawkins DS;
Pediatr Blood Cancer; 2021 Mar; 68(3):e28832. PubMed ID: 33245207
[TBL] [Abstract][Full Text] [Related]
53. Which patients with microscopic disease and rhabdomyosarcoma experience relapse after therapy? A report from the soft tissue sarcoma committee of the children's oncology group.
Smith LM; Anderson JR; Qualman SJ; Crist WM; Paidas CN; Teot LA; Pappo AS; Link MP; Grier HE; Wiener ES; Breneman JC; Raney RB; Maurer HM; Donaldson SS
J Clin Oncol; 2001 Oct; 19(20):4058-64. PubMed ID: 11600608
[TBL] [Abstract][Full Text] [Related]
54. [Rhabdomyosarcoma in middle to old-aged patients: analysis of clinicopathological features and prognosis in 76 cases].
Yu L; Wang J
Zhonghua Zhong Liu Za Zhi; 2012 Dec; 34(12):910-6. PubMed ID: 23336377
[TBL] [Abstract][Full Text] [Related]
55. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group.
Sorensen PH; Lynch JC; Qualman SJ; Tirabosco R; Lim JF; Maurer HM; Bridge JA; Crist WM; Triche TJ; Barr FG
J Clin Oncol; 2002 Jun; 20(11):2672-9. PubMed ID: 12039929
[TBL] [Abstract][Full Text] [Related]
56. Clinical features and prognosis of paediatric rhabdomyosarcoma with bone marrow metastasis: a single Centre experiences in China.
Huang C; Jian B; Su Y; Xu N; Yu T; He L; Zhang X; Liu Y; Jin M; Ma X
BMC Pediatr; 2021 Oct; 21(1):463. PubMed ID: 34670517
[TBL] [Abstract][Full Text] [Related]
57. Heparanase activity in alveolar and embryonal rhabdomyosarcoma: implications for tumor invasion.
Masola V; Maran C; Tassone E; Zin A; Rosolen A; Onisto M
BMC Cancer; 2009 Aug; 9():304. PubMed ID: 19715595
[TBL] [Abstract][Full Text] [Related]
58. Additional Benefit of F-18 FDG PET/CT in the staging and follow-up of pediatric rhabdomyosarcoma.
Ricard F; Cimarelli S; Deshayes E; Mognetti T; Thiesse P; Giammarile F
Clin Nucl Med; 2011 Aug; 36(8):672-7. PubMed ID: 21716019
[TBL] [Abstract][Full Text] [Related]
59. The effect of age at diagnosis on outcome in rhabdomyosarcoma.
La Quaglia MP; Heller G; Ghavimi F; Casper ES; Vlamis V; Hajdu S; Brennan MF
Cancer; 1994 Jan; 73(1):109-17. PubMed ID: 8275414
[TBL] [Abstract][Full Text] [Related]
60. Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group.
Hibbitts E; Chi YY; Hawkins DS; Barr FG; Bradley JA; Dasgupta R; Meyer WH; Rodeberg DA; Rudzinski ER; Spunt SL; Skapek SX; Wolden SL; Arndt CAS
Cancer Med; 2019 Oct; 8(14):6437-6448. PubMed ID: 31456361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
